Categories Analysis, Health Care, U.S. Markets News
European competition threatens AbbVie’s run of top-selling Humira
US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to compete in Europe.
Chief Executive Officer Richard Gonzalez, in a conference call, said, “we’ve seen discounting at ranges from as low as 10 percent to as high as around 80 percent.”

According to AbbVie chief, Nordic countries saw the highest cut, especially in a time when the market thinks cheaper biosimilar competition will continue to be strong in the coming year in the continent as well.
Analysts expect the competition to adversely affect, and gain more momentum in 2020, with Mylan NV (MYL), Biogen Inc (BIIB) Amgen Inc (AMGN) and Novartis AG (NOVN) all starting the sales of biosimilar versions of Humira in Europe. this has caused quite a bit of unrest amongst investors, especially when the blockbuster prescription medicine brings in about two-thirds of AbbVie’s top line.
In the US, however, AbbVie is safe, since biosimilar competition is not expected until 2023. Outside the US, the medical giant sees a 26-27% drop in Humira sales next year, more than the earlier expected 18-20% slip.
In the last reported quarter, total Humira sales were 9% higher at $5.12 billion. Apart from it, leukemia drug Imbruvica also exhibited higher-than-expected sales in the period, hitting $972 million — much higher than the analyst consensus of $885.6 million. Maybe, these strong fundamentals could be the reason for the stock not reacting much to the CEO comments, as it remained flat at $79.77 following the outlook.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Delta Air Lines (DAL) Q2 2025 Earnings: Key financials and quarterly highlights
Delta Air Lines (NYSE: DAL) reported its second quarter 2025 earnings results today. Operating revenue remained flat versus the year-ago quarter at $16.64 billion. GAAP net income increased 63% year-over-year
PepsiCo likely to report weak Q2 results as North America demand slumps
After entering fiscal 2025 on a low note, PepsiCo, Inc. (NASDAQ: PEP) is gearing up to publish its second-quarter results. The company is facing sales pressure amid geopolitical tensions and
Bank earnings preview: These banking leaders will report Q2 2025 results next week, what to expect
The earnings season is set to kick off next week with quarterly reports from a number of leading banks. JPMorgan Chase & Co. (NYSE: JPM), Citigroup (NYSE: C) and Wells